Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-90
SponsorBoston University Charles River Campus

About this trial

Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a nearly threefold higher rate of falls compared to neurotypical older adults. There is an urgent need for fall prevention interventions tailored to the unique deficits of individuals with AD. Converging evidence suggests that interventions aiming to reduce fall risk in AD should target both gait and cognition. Rhythmic music interventions, such as Rhythmic Auditory Stimulation (RAS) can harness global brain activation and auditory-motor entrainment to facilitate high-intensity exercise to alleviate AD-related neurocognitive and gait dysfunction. This study aims to assess the neural correlates of gait dysfunction in people with AD, evaluate if baseline neurocognitive impairment is predictive of the effects of RAS, and evaluate RAS benefits for individuals with AD.

Eligibility criteria

Qualifiers

Community-dwelling

Capable of walking short community distances (approximately 10-15 minutes at a time) without assistance from another person or a device (such as a cane).

Able to communicate with researchers

Age 50-90 (inclusive)

Disqualifiers

Presence of significant hearing impairment

Current orthopedic, neurologic or other medical condition that limits the ability to walk.

Trial design

Treatments tested in this trial

  • Metronome

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Boston University Charles River Campus

Lead sponsor

National Institute on Aging (NIA)

Collaborator